Novel approaches for the treatment of small cell lung cancer

Heather Wakelee; Karen Kelly

doi:10.1016/j.hoc.2004.01.001

Novel approaches for the treatment of small cell lung cancer

Heather Wakelee, Karen Kelly

Research output: Contribution to journal › Article

6 Scopus citations

Abstract

SCLC is an aggressive disease that is rapidly fatal in most patients. Novel therapies based on SCLC biology are an attractive approach to augment current regimens. Several agents that attack a variety of targets from within the tumor cell, the extracellular matrix, and the immune system are under investigation. Although the efficacy results have been mixed, these agents are well tolerated. We look forward to the continued evaluation of promising novel agents alone and in combination with chemotherapy, radiation, and other biologic agents.

Original language	English (US)
Pages (from-to)	499-518
Number of pages	20
Journal	Hematology/Oncology Clinics of North America
Volume	18
Issue number	2
DOIs	https://doi.org/10.1016/j.hoc.2004.01.001
State	Published - Apr 2004
Externally published	Yes

ASJC Scopus subject areas

Oncology
Hematology

Access to Document

10.1016/j.hoc.2004.01.001

Fingerprint Dive into the research topics of 'Novel approaches for the treatment of small cell lung cancer'. Together they form a unique fingerprint.

Cite this

Wakelee, H., & Kelly, K. (2004). Novel approaches for the treatment of small cell lung cancer. Hematology/Oncology Clinics of North America, 18(2), 499-518. https://doi.org/10.1016/j.hoc.2004.01.001

@article{c54efa06653a4ab9b31ee7e5071719dc,

title = "Novel approaches for the treatment of small cell lung cancer",

abstract = "SCLC is an aggressive disease that is rapidly fatal in most patients. Novel therapies based on SCLC biology are an attractive approach to augment current regimens. Several agents that attack a variety of targets from within the tumor cell, the extracellular matrix, and the immune system are under investigation. Although the efficacy results have been mixed, these agents are well tolerated. We look forward to the continued evaluation of promising novel agents alone and in combination with chemotherapy, radiation, and other biologic agents.",

author = "Heather Wakelee and Karen Kelly",

year = "2004",

month = apr,

doi = "10.1016/j.hoc.2004.01.001",

language = "English (US)",

volume = "18",

pages = "499--518",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Novel approaches for the treatment of small cell lung cancer

AU - Wakelee, Heather

AU - Kelly, Karen

PY - 2004/4

Y1 - 2004/4

N2 - SCLC is an aggressive disease that is rapidly fatal in most patients. Novel therapies based on SCLC biology are an attractive approach to augment current regimens. Several agents that attack a variety of targets from within the tumor cell, the extracellular matrix, and the immune system are under investigation. Although the efficacy results have been mixed, these agents are well tolerated. We look forward to the continued evaluation of promising novel agents alone and in combination with chemotherapy, radiation, and other biologic agents.

AB - SCLC is an aggressive disease that is rapidly fatal in most patients. Novel therapies based on SCLC biology are an attractive approach to augment current regimens. Several agents that attack a variety of targets from within the tumor cell, the extracellular matrix, and the immune system are under investigation. Although the efficacy results have been mixed, these agents are well tolerated. We look forward to the continued evaluation of promising novel agents alone and in combination with chemotherapy, radiation, and other biologic agents.

UR - http://www.scopus.com/inward/record.url?scp=1942503367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942503367&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2004.01.001

DO - 10.1016/j.hoc.2004.01.001

M3 - Article

C2 - 15094184

AN - SCOPUS:1942503367

VL - 18

SP - 499

EP - 518

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -